Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
TEVA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $45.77B
- P/E (TTM)
- 91.23
- Forward P/E
- 12.53
- EPS (TTM)
- $0.43
- Dividend yield
- None
- Ex-dividend date
- Nov 27, 2017
- 52-week range
- 24.34 – 44.57
- Day range
- 38.30 – 39.91
- Volume / Avg
- 6.81M / 6.31M
- Beta
- —
- Shares outstanding
- 1.17B
52-week range
TEVA stock today
On Nov 20, TEVA ended the session at $39.23, adding $0.69 (1.79%), versus the S&P 500's 3.70% decline. At this level, TEVA sits in the middle of its 52-week range of $24.34 to $44.57: 12.0% below the high, set on Nov 13, 2026 and 61.2% above the low. TEVA is up 25.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 62.0%.
At 91.2x trailing earnings, Teva Pharmaceutical Industries trades above the peer-group median of 43.2x. Its forward P/E of 12.5x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Teva Pharmaceutical Industries
Company profileTeva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Richard D. Francis
- Headquarters
- Tel Aviv-Yafo
- Employees
- 31,173
- Website
- tevapharm.com
Financial highlights
Full financialsIn fiscal 2025, Teva Pharmaceutical Industries generated $17.26 billion in revenue, up 4.3% from fiscal 2024, its 3rd consecutive year of revenue growth. Net income was $1.41 billion, for a net margin of 8.2% versus a median of -9.9% in the prior 5 years. Gross margin was 51.8% (up from 48.7%) and operating margin 12.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $17.26B | $16.54B | $15.85B | $14.93B | $15.88B |
| Growth | +4.32% | +4.40% | +6.17% | -6.00% | -4.69% |
| Net income | $1.41B | $-1.64B | $-559.00M | $-2.45B | $417.00M |
| EPS (diluted) | $1.21 | $-1.45 | $-0.50 | $-2.20 | $0.38 |
Analyst forecast
ForecastConsensus (15 analysts)
buy
Avg. price target
$50.29+28.19%
- Strong buy 4
- Buy 9
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 3, 2026
- EPS actual vs est.
- $0.20 vs $0.70
- Surprise
- -71.43%
Dividends
Dividend history- Annual dividend
- $0.00
- Last payment
- $0.085
- Ex-dividend date
- Nov 27, 2017
TEVA news
All TEVA news- Teva to Present at the 9th Annual Evercore Healthcare Conference, the Piper Sandler 38th Annual Healthcare Conference and Citi’s 2026 Global Healthcare ConferenceGlobeNewswireTEVA, EVR
- Teva Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Teva (TEVA)PR Newswire
- Teva Pharmaceutical Industries Limited Announces Departure of Chief Medical Officer Dr. Eric Hughes on November 17, 2026NasdaqTEVA, MKC.V
- Teva Announces R&D Leadership Transition As Chief Medical Officer DepartsNasdaq
- Teva Announces R&D Leadership Transition; Eric Hughes to Depart the CompanyGlobeNewswire
- EFG, SPOT, TEVA, SE: Large Outflows Detected at ETFNasdaqEFG, SPOT, TEVA, SE
- Teva Pharmaceutical Wins FDA Approval For IGALMI Sublingual Film For At-Home UseNasdaq
- Teva Pharmaceutical Industries Limited (TEVA) R&D Day: Pivot to Growth Strategy, Pipeline and Financial Outlook - SlideshowSeeking Alpha
Teva Pharmaceutical Industries peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ONCBeOne Medicines Ltd. ADR | 390.94 | -2.19% | $44.66B | vs TEVA |
| RPRXRoyalty Pharma plc Class A | 68.45 | +1.08% | $39.36B | vs TEVA |
| ZTSZoetis Inc. Class A | 79.11 | -2.08% | $32.14B | vs TEVA |
| GMABGenmab A/S ADS | 50.60 | -1.46% | $31.20B | vs TEVA |
| INSMInsmed Incorporated | 141.33 | -2.17% | $31.01B | vs TEVA |
| ROIVRoivant Sciences Ltd. | 38.66 | -0.78% | $28.01B | vs TEVA |
| UTHRUnited Therapeutics Corporation | 554.73 | -0.78% | $23.63B | vs TEVA |
| VTRSViatris Inc. | 19.63 | -1.26% | $22.50B | vs TEVA |
Indexes, lists and sector
Teva Pharmaceutical Industries stock FAQ
What is Teva Pharmaceutical Industries's stock price today?
TEVA last traded at $39.23 as of Nov 20, 4:00 PM EST, up 1.79% on the day. Prices are delayed at least 15 minutes.
Does Teva Pharmaceutical Industries pay a dividend?
Yes. Teva Pharmaceutical Industries pays $0.00 per share annually. The most recent dividend of $0.085 had an ex-dividend date of Nov 27, 2017.
What is TEVA's P/E ratio?
TEVA trades at a trailing P/E ratio of 91.23 and a forward P/E of 12.53, compared with a median of 43.2 for its closest peers.
Who is Teva Pharmaceutical Industries's CEO?
Mr. Richard D. Francis is the chief executive officer of Teva Pharmaceutical Industries Limited, which has about 31,173 employees.
Has TEVA ever split its stock?
Yes. The most recent TEVA stock split was a 2-for-1 split on Jul 1, 2004, one of 4 splits on record.
What is the TEVA 52-week high?
The 52-week high for TEVA is $44.57 and the 52-week low is $24.34. The stock is currently 12.0% below its high.